drugset / Trial / NCT01859962
Study of PPI-668, BI 207127 and Faldaprevir, With and Without Ribavirin, in the Treatment of Chronic Hepatitis C
RandomizedParallel-groupTriple-blindTreatment
Summary
This study is designed to provide a preliminary assessment of the safety and effectiveness of the combination of PPI-668, BI 207127 and faldaprevir, with or without ribavirin, in the treatment of chronic hepatitis C virus infection.
Timeline
- Start
- 2013-05
- Primary completion
- 2014-05
- Completion
- 2014-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Deleobuvir | Small molecule | — | — |
| Comparator | Ribavirin | Small molecule | — | — |
| Comparator | Faldaprevir | Small molecule | — | — |
| Comparator | Ravidasvir | Small molecule | — | — |